The 10-second takeaway
For the quarter ended Sep. 30 (Q3), Luminex missed estimates on revenues and missed estimates on earnings per share.
Compared to the prior-year quarter, revenue grew and GAAP earnings per share shrank.
Gross margins expanded, operating margins shrank, net margins contracted.
Luminex booked revenue of $50.0 million. The nine analysts polled by S&P Capital IQ anticipated sales of $51.3 million on the same basis. GAAP reported sales were 9.9% higher than the prior-year quarter's $45.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.04. The nine earnings estimates compiled by S&P Capital IQ anticipated $0.07 per share. GAAP EPS of $0.04 for Q3 were 20% lower than the prior-year quarter's $0.05 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 70.0%, 320 basis points better than the prior-year quarter. Operating margin was 6.7%, 390 basis points worse than the prior-year quarter. Net margin was 3.3%, 90 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $59.4 million. On the bottom line, the average EPS estimate is $0.11.
Next year's average estimate for revenue is $207.4 million. The average EPS estimate is $0.34.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 91 members out of 104 rating the stock outperform, and 13 members rating it underperform. Among 29 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 24 give Luminex a green thumbs-up, and five give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Luminex is outperform, with an average price target of $20.83.
- Add Luminex to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
3 Top Medical Instrument Companies to Buy in 2017
Baxter, Hill-Rom, and Luminex stand out as top medical instrument stocks to check out.
The Best Stocks in Gene Sequencing
A closer look at gene sequencing stocks -- and how you could score a double helix of gains
Why Luminex Corporation Shares Got Slashed
Luminex reported solid fourth quarter and full year earnings, however, guidance disappointed investors.